Hypercholesterolemia affects over 34 million adults in the United States and is a major cause of coronary heart disease (CHD). Conventional therapies, such as statins, have demonstrated their ability to improve clinical end points and decrease morbidity and mortality in patients with CHD. Lomitapide (Juxtapid®), mipomersen (Kynamro®), and icosapent (Vascepa®) are 3 novel agents approved by the US Food and Drug Administration in the past 2 years, which offer new lipid-lowering treatment options with unique pharmacology.
National Cholesterol Education Program (NCEP)Expert Panel o Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report on the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III): final report. Circulation. 2002;106(25):3143–3421.
2.
CarrollMKitBLacherD. Total and high density lipoprotein cholesterol in adults. National Health and Nutrition Examination Survey, 2009-2010. NCHS Data Brief. No 92; April 2012.www.cdc.gov/nchs/data/databriefs/db92.pdf. Accessed June 30, 2013.
3.
Lloyd-JonesDMLarsonMGBeiserA. Lifetime risk of developing coronary heart disease. Lancet. 1999;353(9147):89–92.
4.
RossLARossBSEastH. Dyslipidemia. In: WoffordMRPoseyLMLinnWDO'KeefeME, eds. Pharmacotherapy in Primary Care. New York: McGraw-Hill; 2009: chap 6. http://www.accesspharmacy.com/content.aspx?aID=3601377. Accessed July 9, 2013.
5.
WilsonPWFD'AgostinoRBLevyD. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–1847.
6.
StamlerJWentworthDNeatonJD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? findings in 356 222 primary screenees of the multiple risk factor intervention trial (MRFIT). JAMA. 1986;256(20):2823–2828.
7.
Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. I: reduction in the incidence of coronary heart disease. JAMA. 1984;251(3):351–364.
8.
Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. II: the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251(3):365–374.
9.
KeysAArvanisCBlackburnH. Seven Countries: A Multivariate Analysis of Death and Coronary Heart Disease. Cambridge, MA: Harvard University Press; 1980:381.
10.
LawMRWaldNJThompsonSG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?BMJ. 1994;308(6925):367–372.
11.
LawMR. Lowering heart disease risk with cholesterol reduction: evidence from observational studies and clinical trials. Eur Heart J Suppl. 1999;1(suppl S): S3–S8.
12.
GrundySMWilhelmsenLRoseG. Coronary heart disease in high-risk populations: lessons from Finland. Eur Heart J. 1990;11(5):462–471.
13.
People’s Republic of China-United States Cardiovascular and Cardiopulmonary Epidemiology Research Group. An epidemiological study of cardiovascular and cardiopulmonary disease risk factors in four populations in the People's Republic of China: baseline report from the P.R.C.-U.S.A. collaborative study. Circulation. 1992;85(3):1083–1096.
14.
LawMRThompsonSGWaldNJ. Assessing possible hazards of reducing serum cholesterol. BMJ. 1994;308(6925):373–379.
15.
LawMRWaldNJWuT. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. BMJ. 1994;308(6925):363–366.
16.
AustinMAHokansonJEEdwardsKL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998;81(4A):7B–12B.
17.
AssmannGSchulteHFunkeH. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J. 1998;19(suppl M): M8–M14.
18.
GordonDJProbstfieldJLGarrisonRJ. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation. 1989;79(1):8–15.
19.
AustinMAHokansonJEEdwardsKL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol. 1998;81(4A):7B–12B.
20.
AssmannGSchulteHFunkeH. The emergence of triglycerides as a significant independent risk factor in coronary artery disease. Eur Heart J. 1998;19(suppl M): M8–M14.
21.
HulleySBRosenmanRHBawolRD. Epidemiology as a guide to clinical decisions: the association between triglyceride and coronary heart disease. N Engl J Med. 1980;302(25):1383–1389.
22.
KraussRM. Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol. 1998;81(4A):13B–17B.
23.
NordestgaardBGLewisB.Intermediate density lipoprotein levels are strong predictors of the extent of aortic atherosclerosis in the St. Thomas’s Hospital rabbit strain. Atherosclerosis. 1991;87(1):39–46.
24.
BreslowJL. Mouse models of atherosclerosis. Science. 1996;272(5262):685–688.
25.
WeisgraberKHInnerarityTLRallSC. Atherogenic lipoproteins resulting from genetic defects of apolipoproteins B and E. Ann N Y Acad Sci. 1990;598:37–48.
26.
MahleyRWWeisgraberKHInnerarityTLRallSCJr. Genetic defects in lipoprotein metabolism: elevation of atherogenic lipoproteins caused by impaired catabolism. JAMA. 1991;265(1):78–83.
27.
TatamiRMabuchiHUedaK. Intermediate-density lipoprotein and cholesterol-rich very low density lipoprotein in angiographically determined coronary artery disease. Circulation. 1981;64(6):1174–1184.
28.
SteinerGSchwartzLShumakS. The association of increased levels of intermediate-density lipoproteins with smoking and with coronary artery disease. Circulation. 1987;75(1):124–130.
29.
StoneNJ. Secondary causes of hyperlipidemia. Med Clin North Am. 1994;78(1):117–141.
HeissGTamirIDavisCE. Lipoprotein-cholesterol distributions in selected North American populations: the lipid research clinics program prevalence study. Circulation. 1980;61(2):302–315.
32.
TornvallPBavenholmPLandouC. Relation of plasma levels and composition of apolipoprotein B-containing lipoproteins to angiographically defined coronary artery disease in young patients with myocardial infarction. Circulation. 1993;88(5 pt 1):2180–2189.
33.
HavelRJ. Remnant lipoproteins as therapeutic targets. Curr Opin Lipidol. 2000;11(6):615–620.
34.
ReardonMFNestelPJCraigIH. Lipoprotein predictors of the severity of coronary artery disease in men and women. Circulation. 1985;71(5):881–888.
35.
PlumpASScottCJBreslowJL. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in apolipoprotein E-deficient mouse. Proc Natl Acad Sci USA. 1994;91(20):9607–9611.
36.
PyöräläKPedersenTRKjekshusJ. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the scandinavian simvastatin survival study (4 S). Diabetes Care. 1997;20(4):614–620.
37.
GoldbergRBMelliesMJSacksFM. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation. 1998;98(23):2513–2519.
38.
Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349–1357.
39.
DownsJRClearfieldMWeisS. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279(20):1615–1622.
40.
GrundySM. Cholesterol-lowering trials: a historical perspective. In: GrundySM, ed. Cholesterol Lowering Therapy: Evaluation of Clinical Trial Evidence. New York: Marcel Dekker Inc.; 2000:1–329.
41.
SacksFMTonkinAMShepherdJ. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the prospective pravastatin pooling project. Circulation. 2000;102(16):1893–1900.
42.
ZimmermanC. Encouraging generic use can yield significant savings. Find Brief. 2012;15(8):1–3.
43.
Merck. FDA approves Merck's Liptruzet (ezetimibe and atorvastatin), a new product that can help powerfully lower LDL cholesterol [press release]. http://www.mercknewsroom.com/search/s/liptruzet. Accessed June 3, 2013.
Lovaza (Omega-3-Acid Ethyl Esters)Prescribing Information [package insert]. Research Triangle Park, NC: GlaxoSmithKline; June2013.
46.
HarrisWSGinsbergHNArunakulN. Safety and efficacy of Omacor in severe hypertriglyceridemia. J Cardiovasc Risk. 1997;4(5-6):385–391.
47.
PownallHJBrauchiDKilnicC. Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins. Atherosclerosis. 1999;143(2):285–297.
48.
KoskiR. Omega-3 acid ethyl esters (Lovaza) for severe hypertriglyceridemia. 2008;33(5):271–303.
GoldsteinJLHobbsHHBrownMS. Familial hypercholesterolemia. In: ScriverCRBeaudetALSlyWSValleD, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill; 2001:2863–2913.
53.
IllingworthDRDuellPBConnorWE. Disorders of lipid metabolism. In: FeligPBaxterJDFrohminLA, eds. Endocrinology and Metabolism. New York, NY: McGraw-Hill; 1995:1315–1403.
MarksDThorogoodMNeilHA. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis. 2003;168(1):1–14.
SamahaFFMcKenneyJBloedonLT. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nature Clin Pract. 2008;5(8):497–505.
60.
CuchelMMeagherEAdu Toit TheronH. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet. 2013;381(9860):40–46.
SteinEADufourRGagneC. Apolipoprotein B synthesis inhibitor with mimpomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation. 2012;126(19):2283–2292.
RaalFJSantosRDBlomDJ. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trail. Lancet. 2010;375(9719):998–1006.
65.
McGowanMTardifJCeskaR. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS ONE. 2012;7(11): e49006.
66.
BaysHEBallantyneCMKasteleinJJ. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the multi-center, placebo-controlled, randomized, double-blind, 12-week study with an open-label extension [MARINE] trial). Am J Cardiol. 2011;108(5):682–690.
67.
BallantyneCMBaysHEKasteleinJJ. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012;110(7):984–992.
